Advanced Control Specialty Formulary®

The CVS Caremark® Advanced Control Specialty Formulary® is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase *Italics*, and generic products in lowercase *italics*.

PLAN MEMBER

Your benefit plan provides you with a prescription benefit program administered by CVS Caremark. Ask your doctor to consider prescribing, when medically appropriate, a preferred medicine from this list. Take this list along when you or a covered family member sees a doctor.

Please note:

- Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the U.S. Food and Drug Administration (FDA) may not be covered upon release to the market.
- Your prescription benefit plan design may alter coverage of certain products or vary copay¹ amounts based on the condition being treated.
- You may be responsible for the full cost of non-formulary products that are removed from coverage.
- For specific information regarding your prescription benefit coverage and copay¹ information, please visit <u>Caremark.com</u> or contact a CVS Caremark Customer Care representative.
- CVS Caremark may contact your doctor after receiving your
 prescription to request consideration of a drug list product or
 generic equivalent. This may result in your doctor prescribing,
 when medically appropriate, a different brand-name product or
 generic equivalent in place of your original prescription.
- In most instances, a brand-name drug for which a generic product becomes available will be designated as a nonpreferred option upon release of the generic product to the market.

HEALTH CARE PROVIDER

Your patient is covered under a prescription benefit plan administered by CVS Caremark. As a way to help manage health care costs, authorize generic substitution whenever possible. If you believe a brand-name product is necessary, consider prescribing a brand name on this list.

Please note:

- · Generics should be considered the first line of prescribing.
- The member's prescription benefit plan design may alter coverage of certain products or vary copay¹ amounts based on the condition being treated.
- This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. The member's specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the FDA may not be covered upon release to the market.
- The member's prescription benefit plan may have a different copay¹ for specific products on the list.
- Unless specifically indicated, drug list products will include all dosage forms.
- Log in to <u>Caremark.com</u> to check coverage and copay¹ information for a specific medicine.

ANALGESICS

VISCOSUPPLEMENTS
GEL-ONE
GELSYN-3
SUPARTZ FX
VISCO-3

ANTI-INFECTIVES

ANTIRETROVIRAL AGENTS § ANTIRETROVIRAL

COMBINATIONS abacavir-lamivudine lamivudine-zidovudine

ATRIPLA BIKTARVY CIMDUO DESCOVY DOVATO EVOTAZ GENVOYA

ODEFSEY

PREZCOBIX SYMFI SYMFI LO SYMTUZA TEMIXYS TRIUMEQ TRUVADA FUSION INHIBITORS

FUZEON

EDURANT

INTELENCE

INTEGRASE INHIBITORS

ISENTRESS TIVICAY

§ NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS efavirenz nevirapine nevirapine ext-rel § NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS abacavir tablet

didanosine lamivudine stavudine zidovudine EMTRIVA

§ NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS

tenofovir disoproxil fumarate

§ PROTEASE INHIBITORS atazanavir lopinavir-ritonavir solution KALETRA TABLET NORVIR PREZISTA

ANTIVIRALS

§ HEPATITIS B AGENTS entecavir lamivudine tenofovir disoproxil fumarate BARACLUDE SOLUTION VEMLIDY

§ HEPATITIS C AGENTS ribavirin EPCLUSA (genotypes 1, 2, 3, 4, 5, 6) HARVONI (genotypes 1, 4, 5, 6) VOSEVI ²

ANTINEOPLASTIC AGENTS

§ ALKYLATING AGENTS temozolomide

§ ANTIMETABOLITES capecitabine

HORMONAL ANTINEOPLASTIC AGENTS

§ ANTIANDROGENS

abiraterone ERLEADA NUBEQA XTANDI

NUBEQA XTANDI YONSA

§ LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONISTS leuprolide acetate ELIGARD

IMMUNOMODULATORS
REVLIMID
THALOMID

§ KINASE INHIBITORS erlotinib imatinib mesylate



AFINITOR
BOSULIF
CABOMETYX
COPIKTRA
IBRANCE
IRESSA
KISQALI
KISQALI FEMARA
CO-PACK
RYDAPT

SPRYCEL

SUTENT

TYKERB

VOTRIENT

§ MISCELLANEOUS

bexarotene capsule LYNPARZA ODOMZO RUBRACA ZEJULA ZOLINZA

CARDIOVASCULAR

ANTILIPEMICS
PCSK9 INHIBITORS
PRALUENT

PULMONARY ARTERIAL HYPERTENSION

§ ENDOTHELIN RECEPTOR ANTAGONISTS

ambrisentan bosentan OPSUMIT

§ PHOSPHODIESTERASE INHIBITORS

sildenafil tadalafil

PROSTACYCLIN RECEPTOR AGONISTS

UPTRAVI

PROSTAGLANDIN VASODILATORS ORENITRAM

SOLUBLE GUANYLATE CYCLASE STIMULATORS ADEMPAS CENTRAL NERVOUS SYSTEM

§ ANTICONVULSANTS vigabatrin

§ MOVEMENT DISORDERS

tetrabenazine AUSTEDO INGREZZA

§ MULTIPLE SCLEROSIS

AGENTS
glatiramer
AUBAGIO
BETASERON
COPAXONE
GILENYA
MAYZENT
REBIF
TECFIDERA
TYSABRI
VUMERITY

ENDOCRINE AND METABOLIC

ACROMEGALY SOMATULINE DEPOT SOMAVERT

§ CALCIUM RECEPTOR ANTAGONISTS cinacalcet

CALCIUM REGULATORS
PARATHYROID HORMONES

FORTEO TYMLOS

MISCELLANEOUS PROLIA

CONTRACEPTIVES

PROGESTIN INTRAUTERINE DEVICES KYLEENA MIRENA SKYLA

FERTILITY REGULATORS

GNRH / LHRH ANTAGONISTS CETROTIDE OVULATION STIMULANTS, GONADOTROPINS

GONAL-F OVIDREL

GAUCHER DISEASE

CERDELGA CEREZYME

HEREDITARY TYROSINEMIA
TYPE 1 AGENTS

ORFADIN

HUMAN GROWTH HORMONES HUMATROPE

POLYNEUROPATHY

TEGSEDI

§ UREA CYCLE DISORDERS sodium phenylbutyrate

MISCELLANEOUS CYSTAGON

HEMATOLOGIC

HEMATOPOIETIC GROWTH FACTORS

ARANESP NEULASTA NIVESTYM RETACRIT UDENYCA

HEMOPHILIA A AGENTS ADYNOVATE

JIVI KOGENATE FS KOVALTRY NOVOEIGHT NUWIQ

HEMOPHILIA B AGENTS REBINYN

THROMBOCYTOPENIA AGENTS MULPLETA

IMMUNOLOGIC AGENTS

ALLERGENIC EXTRACTS
ORALAIR

AUTOIMMUNE AGENTS

See Table 1 for Indication Based Coverage Details

ANKYLOSING SPONDYLITIS
COSENTYX

ENBREL HUMIRA

CROHN'S DISEASE

HUMIRA STELARA

SUBCUTANEOUS #

After failure of HUMIRA

PSORIASIS HUMIRA OTEZLA

SKYRIZI STELARA

SUBCUTANEOUS

TALTZ TREMFYA

PSORIATIC ARTHRITIS

COSENTYX ENBREL HUMIRA OTEZLA

RHEUMATOID ARTHRITIS

ENBREL HUMIRA ORENCIA CLICKJECT

ORENCIA SUBCUTANEOUS

RINVOQ XELJANZ XELJANZ XR

ULCERATIVE COLITIS

HUMIRA STELARA SUBCUTANEOUS # XELJANZ # XELJANZ XR #

After failure of HUMIRA

ALL OTHER CONDITIONS

ENBREL HUMIRA

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)

RASUVO

HEREDITARY ANGIOEDEMA

FIRAZYR RUCONEST TAKHZYRO

IMMUNOSUPPRESSANTS

§ ANTIMETABOLITES mycophenolate mofetil mycophenolate sodium

§ CALCINEURIN INHIBITORS

cyclosporine cyclosporine, modified tacrolimus

§ RAPAMYCIN DERIVATIVES

everolimus sirolimus

RESPIRATORY

ALPHA-1 ANTITRYPSIN DEFICIENCY AGENTS PROLASTIN-C

§ CYSTIC FIBROSIS

tobramycin inhalation solution BETHKIS

PULMONARY FIBROSIS

AGENTS ESBRIET OFEV

SEVERE ASTHMA AGENTS

DUPIXENT FASENRA NUCALA XOLAIR

TOPICAL

DERMATOLOGY ATOPIC DERMATITIS DUPIXENT

MOUTH / THROAT / DENTAL AGENTS PROTECTANTS

OPHTHALMIC

RETINAL DISORDERS EYLEA

EYLEA LUCENTIS

MUGARD

QUICK REFERENCE DRUG LIST

Α

abacavir tablet abacavir-lamivudine abiraterone ADEMPAS ADYNOVATE AFINITOR ambrisentan

ARANESP

atazanavir ATRIPLA AUBAGIO AUSTEDO

R

BARACLUDE SOLUTION BETASERON BETHKIS bexarotene capsule BIKTARVY bosentan BOSULIF

C

CABOMETYX capecitabine CERDELGA

CEREZYME
CETROTIDE
CIMDUO
cinacalcet
COPAXONE
COPIKTRA
COSENTYX
cyclosporine

cyclosporine, modified CYSTAGON

D

DESCOVY didanosine DOVATO DUPIXENT E Ν **RETACRIT THALOMID** ı **REVLIMID TIVICAY EDURANT IBRANCE NEULASTA** ribavirin tobramycin efavirenz imatinib mesylate nevirapine **RINVOQ** inhalation solution **ELIGARD INGREZZA** nevirapine ext-rel **TREMFYA RUBRACA EMTRIVA INTELENCE NIVESTYM RUCONEST TRIUMEQ ENBREL NORVIR IRESSA TRUVADA RYDAPT ISENTRESS** entecavir **NOVOEIGHT TYKERB EPCLUSA NUBEQA** S **TYMLOS** J **ERLEADA NUCALA TYSABRI** sildenafil erlotinib JIVI **NUWIQ** sirolimus **ESBRIET** U **SKYLA** 0 Κ everolimus **SKYRIZI UDENYCA EVOTAZ ODEFSEY** KALETRA TABLET sodium phenylbutyrate **UPTRAVI EYLEA ODOMZO KISQALI** SOMATULINE DEPOT **OFEV** KISQALI FEMARA ٧ **SOMAVERT OPSUMIT** CO-PACK **SPRYCEL VEMLIDY ORALAIR FASENRA** KOGENATE FS stavudine vigabatrin ORENCIA CLICKJECT **FIRAZYR KOVALTRY STELARA** VISCO-3 **FORTEO ORENCIA KYLEENA SUBCUTANEOUS** VOSEVI2 **FUZEON SUBCUTANEOUS** SUPARTZ FX **VOTRIENT** L ORENITRAM **SUTENT** G **VUMERITY ORFADIN** lamivudine **SYMFI OTEZLA GEL-ONE** lamivudine-zidovudine X **SYMFILO OVIDREL GELSYN-3** leuprolide acetate **SYMTUZA XELJANZ GENVOYA** lopinavir-ritonavir solution XELJANZ XR **GILENYA LUCENTIS** Т **XOLAIR PRALUENT** glatiramer LYNPARZA tacrolimus **XTANDI GONAL-F PREZCOBIX** tadalafil M **PREZISTA** Υ **TAKHZYRO** PROLASTIN-C MAYZENT **TALTZ** YONSA **HARVONI PROLIA MIRENA TECFIDERA HUMATROPE MUGARD** Z **TEGSEDI** R **HUMIRA MULPLETA TEMIXYS ZEJULA RASUVO** mycophenolate mofetil temozolomide zidovudine **REBIF** mycophenolate sodium tenofovir disoproxil fumarate **ZOLINZA REBINYN** tetrabenazine

PREFERRED OPTIONS FOR EXCLUDED SPECIALTY MEDICATIONS 3

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
ADCIRCA	sildenafil, tadalafil	EPIVIR HBV	entecavir, lamivudine, tenofovir disoproxil fumarate,
ALIQOPA	COPIKTRA		BARACLUDE SOLUTION, VEMLIDY
ALPROLIX	Consult doctor	EPOGEN	ARANESP, RETACRIT
ASTAGRAF XL	tacrolimus	EUFLEXXA	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
AVONEX	glatiramer, AUBAGIO, BETASERON, COPAXONE, GILENYA, MAYZENT. REBIF. TECFIDERA. TYSABRI. VUMERITY	EXTAVIA	glatiramer, AUBAGIO, BETASERON, COPAXONE, GILENYA, MAYZENT, REBIF, TECFIDERA, TYSABRI, VUMERITY
BARACLUDE TABLET	entecavir, lamivudine, tenofovir disoproxil fumarate, BARACLUDE SOLUTION, VEMLIDY	FOLLISTIM AQ	GONAL-F
		FULPHILA	NEULASTA, UDENYCA
BERINERT	FIRAZYR, RUCONEST	GENOTROPIN	HUMATROPE
BUPHENYL	sodium phenylbutyrate	GLEEVEC	imatinib mesylate, BOSULIF, SPRYCEL
CELLCEPT	mycophenolate mofetil, mycophenolate sodium	GRANIX	NIVESTYM
CHORIONIC GONADOTROPIN	OVIDREL	HEPSERA	entecavir, lamivudine, tenofovir disoproxil fumarate, BARACLUDE SOLUTION, VEMLIDY
COMPLERA	ATRIPLA, BIKTARVY, GENVOYA, ODEFSEY, SYMFI,	HYALGAN	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
	SYMFI LO, SYMTUZA, TRIUMEQ	LETAIRIS	ambrisentan, bosentan, OPSUMIT
DUROLANE	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	LILETTA	KYLEENA, MIRENA, SKYLA
ELELYSO	CERDELGA, CEREZYME	LUPRON DEPOT (For Prostate Cancer Only)	ELIGARD
ELOCTATE	ADYNOVATE, JIVI, KOGENATE FS, KOVALTRY,		
ENVARSUS XR	NOVOEIGHT, NUWIQ tacrolimus	MAVYRET	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI ²



DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
MONOVISC	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	REVATIO	sildenafil, tadalafil
MYFORTIC	mycophenolate mofetil, mycophenolate sodium	SABRIL	vigabatrin
NEUPOGEN	NIVESTYM	SAIZEN	HUMATROPE
NORDITROPIN	HUMATROPE	SANDOSTATIN LAR	SOMATULINE DEPOT, SOMAVERT
NOVAREL	OVIDREL	STRIBILD	ATRIPLA, BIKTARVY, GENVOYA, ODEFSEY, SYMFI,
NUTROPIN AQ	HUMATROPE	SYMFILC	SYMFI LO, SYMTUZA, TRIUMEQ
OMNITROPE	HUMATROPE	SYNVISC, SYNVISC-ONE	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
ORTHOVISC	GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	TASIGNA	imatinib mesylate, BOSULIF, SPRYCEL
	,	TOBI, TOBI PODHALER	tobramycin inhalation solution, BETHKIS
OTREXUP	RASUVO	VIEKIRA PAK	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6).
PEGASYS	Consult doctor	VIENIKA PAN	HARVONI (genotypes 1, 2, 3, 4, 5, 6)
PLEGRIDY	glatiramer, AUBAGIO, BETASERON, COPAXONE, GILENYA, MAYZENT, REBIF, TECFIDERA, TYSABRI, VUMERITY	XENAZINE	tetrabenazine, AUSTEDO
PREGNYL	OVIDREL	ZARXIO	NIVESTYM
PROCRIT	ARANESP. RETACRIT	ZEMAIRA	PROLASTIN-C
PROCYSBI	CYSTAGON	ZEPATIER	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)
PROGRAF	tacrolimus	ZORTRESS	everolimus, sirolimus
RAPAMUNE	everolimus, sirolimus	ZYDELIG	COPIKTRA
RAVICTI	sodium phenylbutyrate	ZYTIGA	abiraterone, XTANDI, YONSA
REPATHA	PRALUENT		

TABLE 1 - PREFERRED OPTIONS FOR INDICATION BASED AUTOIMMUNE EXCLUDED MEDICATIONS

CONDITION	EXCLUDED DRUG NAME(S)	PREFERRED OPTION(S)
ANKYLOSING SPONDYLITIS	CIMZIA SIMPONI TALTZ	COSENTYX ENBREL HUMIRA
CROHN'S DISEASE	CIMZIA ENTYVIO	HUMIRA STELARA SUBCUTANEOUS #
PSORIASIS	CIMZIA COSENTYX ENBREL	HUMIRA OTEZLA SKYRIZI STELARA SUBCUTANEOUS TALTZ TREMFYA
PSORIATIC ARTHRITIS	CIMZIA ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS SIMPONI STELARA SUBCUTANEOUS TALTZ XELJANZ XELJANZ XR	COSENTYX ENBREL HUMIRA OTEZLA
RHEUMATOID ARTHRITIS	ACTEMRA CIMZIA KINERET ORENCIA INTRAVENOUS SIMPONI	ENBREL HUMIRA ORENCIA CLICKJECT ORENCIA SUBCUTANEOUS RINVOQ XELJANZ XELJANZ XR
ULCERATIVE COLITIS	ENTYVIO SIMPONI	HUMIRA STELARA SUBCUTANEOUS # XELJANZ # XELJANZ XR #
ALL OTHER CONDITIONS	ACTEMRA KINERET ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS	ENBREL HUMIRA

After failure of HUMIRA



You may be responsible for the full cost of certain non-formulary products that are removed from coverage. Please check with your plan sponsor for more information.

FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. New-to-market products and new variations of products already in the marketplace will not be added to the formulary immediately. Each product will be evaluated for clinical appropriateness and cost-effectiveness. Recommended additions to the formulary will be presented to the CVS Caremark National Pharmacy and Therapeutics Committee (or other appropriate reviewing body) for review and approval. In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. Specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. The member's prescription benefit plan may have a different copay¹ for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. Generics listed in therapeutic categories are for representational purposes only. Listed products may be available generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to Caremark.com to check coverage and copay¹ information for a specific medicine.

- * The preferred options in this list are a broad representation within therapeutic categories of available treatment options and do not necessarily represent clinical equivalency.
- § Generics are available in this class and should be considered the first line of prescribing.
- 1 Copayment, copay or coinsurance means the amount a member is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.
- ² For use in patients previously treated with an HCV regimen containing an NS5A inhibitor (for genotypes 1-6) or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
- 3 An exception process is in place for specific clinical or regulatory circumstances that may require coverage of an excluded medication.

CVS Caremark may receive rebates, discounts and service fees from pharmaceutical manufacturers for certain listed products. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2020 CVS Caremark. All rights reserved. 106-31697C 100120

Caremark.com

